Regulatory and Legislative Crackdown on PBMs and Vertical Integration
The highly profitable business model of vertically integrated managed care organizations—which combines health insurance, Pharmacy Benefit Managers (PBMs), and retail/specialty pharmacies—is facing an unprecedented, multi-front legislative, regulatory, and legal assault in mid-2026.
Federal and state policymakers are directly targeting the common ownership of PBMs and pharmacies, which has historically allowed insurers to lock out independent pharmacies and steer patients to their own higher-cost specialty channels. On May 13, 2026, the bipartisan Patients Before Monopolies Act (PBM Act) was re-introduced in both chambers of Congress. The 2026 version of the bill makes it unlawful to own or control both a pharmacy and an insurance company or PBM, and introduces severe new enforcement teeth:
- Accelerated Divestment: Shortens the divestment period for common ownership violations from three years to just one year.
- Financial Penalties: Non-compliant entities must transfer 10% of their monthly profits into an escrow account until divestiture is complete.
- Private Right of Action: Grants individuals the right to sue violating entities for treble damages and attorney fees.
At the state level, Tennessee enacted the Freedom, Access, and Integrity in Registered Pharmacy (FAIR Rx) Act (S.B. 2040) on May 22, 2026. This law bans any entity from directly or indirectly owning more than a 5% interest in both a pharmacy and a PBM or health insurer, effective July 1, 2028. Tennessee follows Arkansas, which passed a similar ban that is currently being appealed in the Eighth Circuit.
In response, PBMs are fighting back in the courts while voluntarily modifying their pricing to stave off forced breakups. On May 8, 2026, Optum Rx (UNH's PBM) and GPO Emisar Pharma Services filed a lawsuit to block California's S.B. 41 (a major PBM reform bill signed in October 2025). Optum Rx argues that the law's formulary exclusivity restrictions, anti-steering mandates, and spread-pricing bans are preempted by ERISA, echoing a recent Sixth Circuit ruling (McKee Foods Corp. v. BFP Inc.) that struck down Tennessee's pharmacy laws.
Simultaneously, Optum Rx announced a voluntary "transparent pharmacy care model" on May 11, 2026. This model shifts clients to flat, per-member-per-month (PMPM) administrative fees independent of drug prices or prescription volumes, while providing full transparency into manufacturer rebates and GPO fees. This voluntary pivot—similar to CVS's TrueCost model—is a direct effort to preserve vertical integration by sacrificing lucrative spread-pricing margins in exchange for regulatory survival.